Strong margins mask weak revenue; guidance cut leaves FY27 path opaque

11.6% YoY growth trails prior 30% FY27 guidance significantly

16.29% EBITDA vs. stated sustainable 10–12%; management admits exceptional

Q1 annualized ~₹380 Cr; path to ₹1,000 Cr by FY28 requires 15%+ Q growth from H2, undemonstrated

Confirmed; capex ₹2 Cr; no revenue contribution quantified yet

Prior call: minimum 30% FY27 growth. Q1: 11.6% YoY. No re-statement of FY27 target; replaced with vague ₹1,000 Cr FY28 aspiration. Implicit cut.

Q1 EBITDA 16.3% vs. prior guided 10–12% sustainable. MD now says 10–12% 'normal' but 16% possible via product mix. Upside flagged but hedged as exceptional.

Added 3,550 MT/annum at ₹2 Cr capex, already operational. Existing utilization 64%; expansion aims to support future verticals (IBC, Furnastra).

New vertical launching Q3 FY27 with separate machinery & capex (not yet quantified). MD cautious: 'test the water' on demand.

All verticals doing well. Expansion plans up; in line with ₹1,000 Cr announcement. Expanding capacity.

Innovation, efficiency, product mix. Suppliers raising prices; passing on to customers who understand geopolitical situation. Generally 10–12% sustainable; 16% exceptional.

~₹2 Cr capex; internal accruals & debt. Already operational. FY27: looking for same growth quarter-on-quarter; more focus on bottom line than top line.

Agree fully. Q1 low. Top line in mind but focusing on bottom line. IBC coming Q3; all in line with growth. Will find revenue growth very soon.

Seasonality: max 85% possible. Blow/injection molding industry needs 6–9 months lead time from order to commercialization. Must plan ahead with infrastructure.

Q3 most probably. Good opportunity, new product. Separate machinery. Capex details to come soon.

No, other expenses too. Operating efficiency, product mix, value addition. Raw material pass-through ~monthly, case-by-case basis for specialized customers.

Takes time to establish in intl. market. Already entered; results awaiting. Ongoing process.

Generally 10–12% normal. All efficiency & product optimization ongoing. Double-digit will remain; how much grows quarter-to-quarter TBD. Will try sustain as best possible.

All verticals growing. Furniture parts/others growing; expect more revenue sharing in furniture than containers. 80–20 ratio likely remains same even at ₹1,000 Cr.

Stated as long-term aspiration; no path quantified. Requires ~15%+ Q growth from H2 FY27 onwards vs. Q1's 11.6%. IBC & Furnastra ramp are bets, not certainties.

Management vague; says 'very soon' acceleration expected but no specifics. IBC Q3 launch could drive H2 acceleration, but unproven demand.

Q1 16.3% attributed to product mix & efficiency. MD acknowledges volatility; double-digit EBITDA 'will remain' but quarter-to-quarter variation expected.

IBC capex TBD; MD says 'announce very soon.' Funded via internal accruals & debt.

Prior call guided minimum 30% FY27 revenue growth. Q1 delivered 11.6% YoY. No restated FY27 target; ₹1,000 Cr FY28 aspiration unquantified.

Q1 EBITDA 16.3% above stated 10–12% sustainable range. MD attributes to product mix & efficiency. Risk: mix normalizes or raw material cost-pass-through breaks under customer pushback.

IBC (Intermediate Bulk Container) launching Q3 FY27 with separate machinery & capex (TBD). MD cautious: 'test the water' on market demand. High execution risk given new product, new machinery, new market.

Adding 3,550 MT/annum capacity while existing utilization at 64% in FY26. Analyst questioned why expand rather than optimize current 64% to 70–90%.

Exports only ~2% of ₹95.1 Cr (₹1.9 Cr). Furnastra global opportunity (hospital furniture) cited as long-term growth driver but timeline vague, results 'awaiting.' 98% domestic revenue concentration.